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ABSTRACT 
Background: Mailed outreach promoting colorectal cancer (CRC) screening with a stool blood 
test kit may increase participation, but magnitude and consistency of benefit of this intervention 
strategy is uncertain.  
Aim: Conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) 
comparing mailed outreach offering stool tests to usual care, clinic-based screening offers on 
CRC screening uptake in the United States.  
Methods: We performed a systematic literature search of 5 databases for RCTs of mailed 
outreach January 1980 through June 2017. Primary outcome was screening completion, 
summarized using random-effects meta-analysis as pooled differences in proportion completing 
screening and relative risk of achieving screening compared to control. Subgroup analyses by 
test type offered--fecal immunochemical test (FIT) or guaiac fecal occult blood test (gFOBT)--, 
presence of telephone reminders, and presence of predominant underserved/minority 
population within study were performed. Quality of evidence was evaluated using the GRADE 
framework.   
Results: 7 RCTs which enrolled 12,501 subjects were included (n=5,703 assigned mailed 
outreach and n=6,798 usual care). Mailed outreach resulted in a 28% absolute (95%CI: 25-
30%; I2=47%), and a 2.8-fold relative (RR 2.65, 95%CI: 2.03-3.45; I2=92%) increase in 
screening completion compared to usual care, with a number needed to invite of 3.6. Similar 
outcomes were observed across subgroups. Overall body of evidence was moderate quality. 
Conclusions:  Mailed outreach offering a gFOBT or FIT is associated with a large and 
consistent increase in CRC screening completion and should be considered for more 
widespread implementation for improving screening rates nationwide.  
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INTRODUCTION 
 Colorectal cancer (CRC) is the 2nd leading cause of cancer deaths in the United 
States.[1, 2] Screening can prevent mortality and morbidity, but is underutilized. The most 
recent National Health Interview Survey (NHIS) found that 62% of the US population is up-to-
date, a proportion significantly lower than the National Colorectal Cancer Roundtable’s goal of 
80% by 2018. Further, examination of data from the last three NHIS surveys from 2011, 2013, 
and 2015 suggest that screening rates are plateauing, ranging from 60-62%.[3]  Evidence-
based strategies are required to optimize screening rates, and deliver the promise of CRC 
screening and prevention to the population.  
The Community Guide to Preventive Services (“Community Guide”) has recommended 
use of multicomponent interventions to promote CRC screening. This is defined as using 
interventions from at least 2 out of the following 3 domains: 1) Interventions to increase 
community demand, such as client reminders, client incentives, small media, mass media, 
group education, one-on-one education; 2) Interventions to increase community access, such 
as reducing structural barriers, reducing client out-of-pocket costs; and 3) Interventions to 
increase provider delivery of screening services, such as provider assessment and feedback, 
incentives, and/or reminders.[4] Mailed outreach offering stool based tests for CRC screening, 
such as guaiac fecal occult blood testing (gFOBT) or fecal immunochemical testing (FIT), 
qualifies as multicomponent as mailed outreach usually includes elements from two of the 
necessary domains: 1) increasing community demand via client reminders and written 
educational materials, and 2) increasing community access by reducing structural barriers 
through the delivery of mailed interventions (usually including a free stool test) which eliminates 
the need for patients to physically go to a medical facility to get the test. More specifically, 
mailed outreach usually consists of identifying individuals not up-to-date with screening within a 
health system, mailing invitations to complete screening with an enclosed stool testing kit, and 
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often telephone or written reminders to complete screening. Within health systems, mailed 
outreach has been shown in multiple randomized trials to significantly increase screening rates. 
Importantly, many of these trials have been done in settings serving low income, uninsured, 
and/or minority populations – groups that have historically low rates of screening.   
Despite promising results, mailed outreach has not been widely implemented, and has 
not been formally endorsed by entities such as the National Colorectal Cancer Roundtable. 
Lack of uptake may be because of varying outcomes, study populations, and type of tests 
offered (FIT or guaiac FOBT) across studies. We postulate that establishing the magnitude and 
consistency of benefit of mailed outreach across study populations and test types might help 
facilitate endorsement and widespread implementation of this strategy for increasing screening 
rates. Accordingly, our aim was to conduct a systematic review and meta-analysis comparing 
the impact of mailed outreach on CRC screening compared to usual care, opportunistic offers 
for screening. We used Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) criteria to appraise the quality of the evidence.  
METHODS 
Approach 
Our overarching goal was to identify randomized controlled trials comparing impact of 
mailed outreach offering stool-based tests to usual care, opportunistic offers for increasing CRC 
screening.  
Selection Criteria:  
 We focused our review on randomized controlled trials only; any observational studies 
were excluded from our review.  The primary population within these trials were patients not up-
to-date with screening.  Studies were included if the primary intervention was mailed outreach 
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offering a stool-based screening test, such as FOBT, FIT, or multi-target stool DNA, and the 
control group was usual care screening, defined as office visit-based opportunistic screening 
offers.  The primary study outcome was the proportion of patients who completed CRC 
screening on follow-up.  Studies were excluded if they featured patients with a higher risk for 
colorectal cancer (i.e., inflammatory bowel disease), focused on interventions for improving 
colonoscopy follow-up after abnormal stool tests, did not include a usual care control group, or 
yielded incomplete data.   
Search Strategy:  
Electronic searches were performed in MEDLINE/PubMed, EMBASE, CINAHL, 
Cochrane Central Register of Controlled Trials, and Google Scholar (using the first 200 results) 
for eligible studies from January 1980 to June 29, 2017. The search strategy included controlled 
vocabulary terms and keyword terms for each of the four concepts: colorectal cancer, screening 
or detection, health promotion methods, and type of trial and were not limited by language. A 
complete description of the search strategies is provided in the Supplementary Materials under 
Search Strategy. The search was updated for PubMed through July 2018 and yielded no 
additional papers meeting inclusion criteria. 
Study Selection:  
Title and abstract review were conducted by a single reviewer by applying preset 
inclusion/exclusion criteria (MJ). Manuscripts were reviewed by two reviewers (MJ, AA), with 
discrepancies being sent to the senior author (SG) for resolution. Only published studies with 
full manuscripts were included. 
Data Extraction:  
 7 
Data extraction was conducted by two reviewers (MJ, AA), with discrepancies being 
resolved via discussion. The following data were extracted from each included study: 1) study 
characteristics, including author, year published; 2) Study population characteristics, including 
whether the study included substantial representation of underserved populations such as 
uninsured and/or minorities, age, proportion female; 3) Interventions utilized, including the test 
offered (gFOBT, FIT, or multi-target stool DNA), number of stool samples requested, telephone 
reminders, and any additional interventions ; 4) Outcomes, including the number of participants 
who completed screening in each group.  
Risk of Bias Assessment 
Risk of bias assessment in these trials was performed using the Cochrane Risk of Bias 
tool. Studies were deemed to be at high, low, or unclear risk of bias based on adequacy of 
sequence generation, allocation concealment, blinding, method of addressing incomplete data, 
selective reporting, and other biases. 
Data Synthesis and Statistical Analysis 
 Primary outcome of interest was completion of CRC screening within nine months to one 
year of intervention. Additionally, we planned a priori to examine results stratified by test type 
used (FIT or gFOBT), presence of telephone reminders as part of the intervention, and whether 
the study population focused on underserved/minority populations.  
We used the random effects model described by DerSimonian and Laird to estimate 
pooled risk difference (magnitude of difference between active intervention and control) and 
relative risk (of achieving outcome as compared to control) and 95% confidence intervals 
(CI).[5] We assessed heterogeneity between study-specific estimates by measuring the 
percentage of variation across studies due to heterogeneity (I2), and used cut-offs of <30%, 
30%-59%, 60%-75% and >75% to suggest low, moderate, substantial and considerable 
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heterogeneity, respectively.  Between-study sources of heterogeneity were assessed in 
subgroup analyses defined above using meta-regression.  A p-value for differences between 
subgroups of <0.10 was considered statistically significant. Due to small number of studies, a 
reliable assessment of publication bias could not be estimated. All analysis was performed 
using Comprehensive Meta-Analysis (CMA) version 3 (Biostat, Englewood, NJ) and Stata 
version 13 (StataCorp, College Station, TX). We estimated number needed to treat (NNT) from 
the summary estimates for the primary outcome, using the median control group risk of studies 
included in the meta-analysis. Specifically, we defined NNT follows: NNT = 1/ (pooled median 
intervention effect – median control group effect). This systematic review is registered at 
PROSPERO, protocol registration number CRD42017070542.  
GRADE Quality of Evidence  
We followed the GRADE approach to appraise the confidence in estimates derived from 
meta-analysis of efficacy outcomes. In this approach, direct evidence from RCTs starts at high 
confidence and can be rated down based on risk of bias, indirectness, imprecision, 
inconsistency (or heterogeneity) and/or publication bias, to levels of moderate, low and, very low 
confidence. Quality of evidence was assessed by two authors (MJ, KS), with discrepant ratings 
resolved by discussion. 
RESULTS 
Search Results 
Our literature search yielded a total of 1,088 candidate studies for inclusion. After title 
review, 725 studies were selected for abstract review. Abstract review yielded 28 studies for 
detailed manuscript review. [6–27]  Of these, 6 were found to be duplicates and 15 did not meet 
inclusion/exclusion criteria[6, 7, 23–27, 8–12, 18, 21, 22], leaving 7 for final inclusion[13–17, 19, 
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20] (see Supplementary Materials, Figure A for search flow, and Table A for exclusion details for 
papers that underwent manuscript review).  
Study characteristics 
The 7 selected RCTs were published between 2004 and 2016, and in total included 
12,501 individuals who were randomly assigned to mailed outreach (n=5,703) or usual care 
(n=6,798). FIT was utilized for 3 of 7 studies and gFOBT for 4 of 7 studies. Sample size ranged 
from 119 to 5,491. Proportion female ranged from 54% to 73%. Underserved populations such 
as those with low income, or who were uninsured or minorities were the focus of 6 out of 7 
studies. See Table 1 for detailed characteristics of included studies. 
Impact of mailed outreach on screening completion 
Mailed outreach offering stool tests was associated with a statistically significant 
absolute improvement in CRC screening in each of the 7 included studies, ranging from 18% to 
36% (Figure 1). Across studies, proportion completing screening ranged from 20- to 9% overall, 
from 2 to 30% among usual care groups, and from 26 to 59% among mailed outreach groups. 
Meta-analysis demonstrated mailed outreach was associated with a 28% absolute increase in 
screening compared to usual care, office visit-based opportunistic offers for screening with 
moderate heterogeneity (95% CI: 25-30%; I2=47%; Figure 1), and 2.65-fold increased chance 
of screening completion (RR 2.65, 95% CI: 2.03-3.45; I2=92%; Figure 2). Based on these 
results, number needed to invite to achieve one additional patient up-to-date with screening was 
estimated to be 3.6.  
Subgroup Analyses 
Analyses stratified by stool test type found the 3 studies offering FIT were associated 
with a 27% absolute increase in screening (95% CI: 23-31%; I2=67%), while the 4 studies 
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offering gFOBT were associated with a 28% increase in screening (95% CI: 23-33%; I2=43%; 
Figure 1). Similar magnitude of screening increases, and p-value for significant difference of 
stool test groups of 0.61 suggested that stool test type had no major impact on efficacy of 
mailed outreach. 
Analyses stratified by presence of telephone reminders found the 4 studies including 
telephone reminders were associated with a similar increase in screening as the 3 studies 
without telephone reminders: absolute increase 27% with reminders (95% CI: 23-31; I2=56%) 
vs. 29% without reminders (95% CI: 23-35; I2=54%); p-value for significant difference in risk = 
0.49.  
Analyses stratified by focus on underserved and/or minority populations found similar 
impact of mailed outreach within settings providing care to populations at high risk for screening 
non-completion. Specifically, the pooled absolute increase in screening observed for the 6 
studies focusing on underserved and/or minority populations was 27% (95% CI: 23-30%; 
I2=49%), while the increase in screening for the 1 study not focusing on underserved/minority 
populations was 31% (95% CI: 27-34; p-value for difference in risk differences = 0.40).  
Quality Assessment:  
 The included studies were judged to be at low (n=3) and moderate (n=4) risk of bias 
(Supplementary Materials, Table B). For studies judged to be at moderate risk of bias, the most 
common limitation was a lack of both participant and provider (double) blinding, but we 
determined that this was unlikely to significantly influence the results of the studies, as the 
screening rates were likely not affected.  Taken together, because the 7 studies included are at 
low/moderate risk of bias, we conclude that the strength of evidence to support effectiveness of 
mailed outreach for promoting CRC screening completion based on this meta-analysis is 
moderate (Supplementary Materials, Table C).    
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DISCUSSION  
In this systematic review and meta-analysis of RCTs comparing mailed outreach 
promoting CRC screening with included stool blood kits to usual care, clinic-based opportunistic 
offers for screening, we observed that mailed outreach was associated with a large pooled 28% 
absolute increase in screening, with moderate confidence in estimates. Overall, this 
corresponds to a number needed to invite of 3.6. The analysis included data contributed by 7 
randomized trials representing over 12,501 patients and showed consistent results. Specifically, 
a similar absolute increase was seen across subgroup analyses stratifying by test offered (FIT 
or gFOBT) and presence of telephone reminders. Remarkably, 6 of 7 studies focused on 
underserved populations, highlighting potential for mailed outreach to improve screening among 
populations with traditionally low screening participation. Taken together, the results suggest 
that mailed outreach offering stool blood tests increases screening completion with a large 
effect size, compared to usual care.  
Our results, together with prior work by others, indicate that mailed outreach should undergo 
more widespread implementation for increasing screening. The 28% pooled absolute increase 
in screening associated with mailed outreach versus usual care compares very favorably with 
other interventions for increasing screening.  For example, the observed increase for mailed 
outreach compared to usual care is superior to that observed for mailed colonoscopy offers 
(10.2%) and visit-based FOBT offers (7.7%)[4]. Furthermore, the 28% screening increase from 
mailed outreach significantly exceeds that interventions such as offering FIT or FOBT at time of 
seasonal Flu vaccination campaigns (15%)[29], patient reminders (5-15%[30], 10%[31]), and 
patient education (17%)[7]. Mailed outreach was comparable to screening increases from 
eliminating structural barriers (15-42%)[30] and one-on-one interactions (15-42%)[30]. The 20 to 
49% range of screening completion in response to mailed outreach observed in the US studies 
included in our review is generally lower than observed in studies from Europe (range 20 to 
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68%) and Asia (range 21 to 63%) [28]. However, the generally lower ranges may be because 
usual care, opportunistic screening is not offered at baseline (individuals offered outreach are 
more likely to be naive to prior screening offers) and because outreach is offered in context of 
national healthcare systems.  
Our results complement other recent systematic reviews of strategies for promoting 
screening. In a comprehensive systematic review of population health interventions to improve 
screening studied by randomized trials or observational studies, Issaka et al. also concluded 
mailed outreach was highly effective relative to other interventions such as offering FIT at time 
of flu vaccination [32]. Similarly, Davis et al. conducted a systematic review of clinic and 
community interventions shown by randomized trials and observational studies to increase stool 
occult blood testing in rural and low-income populations in the United States and concluded 
multicomponent interventions such as mailed outreach were among the most promising 
strategies for boosting screening [33]. These comprehensive systematic reviews of randomized 
and non-randomized studies are complemented by our meta-analysis which quantitatively 
synthesizes the net effect of CRC screening with mailed outreach vs. usual care as reported by 
randomized trials. Dougherty conducted a broad systematic review and meta analysis of 
interventions intended to increase CRC screening rates in the US, and reported that fecal occult 
blood test outreach, defined as mailed outreach or distributing FITs at time of patient encounters 
such as flu vaccination, was associated with 2-fold increased likelihood of screening completion 
[34]. Our meta-analysis is complimentary, but specifically focuses only on mailed outreach, and 
required a usual care comparator arm for all included studies.   Taken together, the 
preponderance of available evidence suggests that mailed outreach should be more strongly 
considered as a strategy for increasing screening. Several limitations should be considered 
when interpreting our results. First, a number of high quality mailed outreach studies were not 
included based on a priori exclusion criteria such as lack of data on screening 9 to 12 months 
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post randomization [9, 25, 26], including individuals with an increased risk of CRC[32], and lack 
of a usual care control group defined as office visit-based opportunistic screening offers to 
patients overdue for CRC screening[12, 27].  Notably, the direction and magnitude of mailed 
intervention effects in these excluded studies were similar to that observed across included 
studies. Second, we focused on studies that utilized usual care, opportunistic screening as a 
control group. We focused on these studies because in the United States, opportunistic 
screening is the most common approach. Additionally, we focused on stool-based tests, since 
this is the most common approach to mailed outreach, though some have shown that mailed 
outreach offering alternate tests such as colonoscopy may also be successful for increasing 
screening[13, 14]. Strengths of this study include our focus on studies relevant to understanding 
the incremental benefit of mailed outreach over usual care, a rigorous a priori search strategy, 
and critical appraisal of quality of evidence as part of our methods. 
Overall, our results suggest that mailed outreach offering either gFOBT or FIT is a highly 
effective, evidence-based strategy for increasing CRC screening, including among underserved 
populations. Given that we are still short of the 80% by 2018 goal set by the National Colorectal 
Cancer Roundtable for population screening, mailed outreach should be strongly considered as 
an additional strategy for increasing screening and be more widely implemented by health 
systems.  
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Figure 1. Absolute increase in CRC screening completion for mailed outreach vs. 
usual care, stratified by test type (FIT or gFOBT). Mailed outreach was associated 
with a pooled absolute increase in screening completion of 28% for all studies, 27% for 
studies employing FIT, and 28% for studies employing gFOBT. Weights are from 
random effects analysis. CRC, colorectal cancer; FIT, fecal immunochemical test; 
gFOBT, guaiac fecal occult blood test; RD, relative difference.  
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Figure 2. Relative increase in CRC screening completion for mailed outreach vs. 
usual care, stratified by test type (FIT or gFOBT). Mailed outreach was associated 
with a pooled 2.6-fold relative increase in screening completion for all studies, a 1.79-
fold relative increase for studies employing FIT, and a 2.18-fold relative increase for 
studies employing gFOBT. Weights are from random effects analysis. CRC, colorectal 
cancer; FIT, fecal immunochemical test; gFOBT, guaiac fecal occult blood test; RD, 
relative difference. 
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